CIK 0001615219 · Non-accelerated filer<br>Smaller reporting company
Decoy Therapeutics Inc.
Sign in to watch- Ticker
- DCOY
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 465087339
- Phone
- 346-772-0346
- Business address
- 2450 HOLCOMBE BLVD, SUITE J-608, HOUSTON, TX, 77021
- Former names
- Salarius Pharmaceuticals, Inc., Flex Pharma, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-08-31 | Gauthier Patricia G. Director | Grant or award | +2,000 | 2,000 | ||
| 2026-08-31 | Marschel Peter Klaus Chief Business Officer | Grant or award | +3,900 | 3,900 | ||
| 2026-08-31 | Hibner Barbara Louise Chief Scientific Officer | Grant or award | +4,216 | 4,216 | ||
| 2026-08-31 | Burleson Tess Director | Grant or award | +2,000 | 2,002 | ||
| 2026-08-31 | McVicar William K. Director | Grant or award | +3,000 | 3,002 | ||
| 2026-08-31 | Lammers Paul Director | Grant or award | +2,000 | 2,001 | ||
| 2026-08-31 | Rosenblum Mark J Chief Financial Officer | Grant or award | +9,682 | 11,363 | ||
| 2026-08-31 | HANISH ARNOLD C Director | Grant or award | +3,000 | 3,418 | ||
| 2026-08-31 | PIERCE FREDERICK II Chief Executive Officer | Grant or award | +33,455 | 34,844 | ||
| 2026-08-31 | Lieber Jonathan I Director | Grant or award | +2,000 | 2,002 | ||
| 2025-12-30 | HANISH ARNOLD C Director | Sale | −15 | $0.64 | $10 | 5,000 |
| 2025-12-30 | HANISH ARNOLD C Director | Sale | −12 | $0.64 | $8 | 0 |
| 2025-11-20 | HANISH ARNOLD C Director | Purchase | +5,000 | $0.75 | $4K | 5,015 |
| 2025-11-20 | Rosenblum Mark J Exec VP Finance, CFO | Purchase | +20,000 | $0.80 | $16K | 20,177 |
| 2024-04-11 | Arthur David J. Chief Executive Officer | Grant or award · Stock Option (right to buy) | +20,500 | 20,500 | ||
| 2024-02-20 | Rosenblum Mark J Exec VP Finance, CFO | Grant or award · Stock Option (right to buy) | +22,500 | 22,500 | ||
| 2024-02-20 | McVicar William K. Director | Grant or award · Stock Option (right to buy) | +20,500 | 20,500 | ||
| 2024-02-20 | McCreedy Bruce J Jr. Director | Grant or award · Stock Option (right to buy) | +20,500 | 20,500 | ||
| 2024-02-20 | Lieber Jonathan I Director | Grant or award · Stock Option (right to buy) | +20,500 | 20,500 | ||
| 2024-02-20 | Lammers Paul Director | Grant or award · Stock Option (right to buy) | +20,500 | 20,500 |
Page 1 of 6 · 107 trades